Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ProTide man Chris McGuigan hopes to make Nucana the next Gilead

This article was originally published in Scrip

Executive Summary

There aren't many privately held UK-based pharmaceutical companies that can boast of appointing an inventor behind one of the world's biggest selling drugs to its management team. But Nucana's new CSO is Professor Chris McGuigan, the man behind ProTides, a technology used in drugs such as Gilead Sciences' Sovaldi (sofosbuvir). Here he tells Scrip what prompted him to cut down on his academic commitments for the first time in his career to take up a management position at a little-known oncology firm.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts